Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06277752
Status:
COMPLETED
Last Update Posted:
2024-03-22
First Post:
2024-02-04
Brief Title:
A Study to Investigate the PharmacokineticPharmacodynamic Characteristics of IBI128A New Xanthine Oxidase Inhibitor
Sponsor:
Innovent Biologics Suzhou Co Ltd
Organization:
Innovent Biologics Suzhou Co Ltd
Study Overview
Official Title:
A Randomized Open-labelSingle Dosing Clinical Trail to Investigate the PharmacokineticPharmacodynamic Characteristics of IBI128 in Chinese Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase I study to evaluate the pharmacokineticpharmacodynamic characteristicssafety and tolerability of IBI128 after multidosing in Chinese health subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None